logo
Why a billionaire investor thinks bitcoin's total market value could more than double to $5 trillion

Why a billionaire investor thinks bitcoin's total market value could more than double to $5 trillion

Business Insider5 hours ago

The total value of all bitcoins could more than double, according to one billionaire investor who says he wishes he had bought the crypto sooner.
Philippe Laffont, the founder of hedge fund Coatue Management, said he added bitcoin to his firm's Fantastic 40 list, a collection of investments it sees as major winners through 2030.
That's partly because Laffont believes the total market cap of the world's biggest crypto could rise to as much as $5 trillion one day. That implies bitcoin's total value rising 134% from a market cap of around $2.1 trillion on Wednesday.
"I have not gotten involved in bitcoin. I wake up every day at 3 in the morning and I'm like, 'why am I such an idiot? What have I been waiting for, not being involved in it?' And it just goes up and up," Laffont told CNBC on Wednesday.
Bitcoin's price has been volatile this year amid tariff-related volatility and a mix of geopolitical and economic concerns. The crypto has rallied to $107,000 in recent days, bringing its price up 14% year-to-date. It hit an all-time high above $111,000 in May.
Laffont, who said he initially brushed off bitcoin as an attractive investment, added that there were a few reasons why he's warming up to the cryptocurrency and sees the value soaring.
For one, bitcoin's current valuation relative to the rest of the world seems too low, according to Laffont.
The net worth of all world assets hovers around $500 trillion, Laffont said. That means bitcoin represents around 0.5% of the world's total assets, but Laffont thinks it's reasonable for bitcoin to represent 1%-2% of the total.
Global stocks, by comparison, make up around $120 trillion of the world's assets, while gold makes up around $20 trillion, he added.
Second, bitcoin's volatility appears to be declining relative to stocks. Bitcoin dropped 11% in the days after President Donald Trump announced his sweeping array of tariffs. That's a slightly less severe decline when compared to the Nasdaq 100, which dropped 12% from April 2 to its low on April 8.
"I always thought, bitcoin's amazing, but it's double or triple the volatility of the Nasdaq," Laffont said. "It seems its volatility as an asset class is coming down."
Third, bitcoin could benefit from concerns around de-dollarization and the end of US exceptionalism.
Global investors have shown some signs that they're less willing to park their wealth in US assets after this year's tariff-fueled sell-off.
More than half of global investors surveyed by Bank of America in June said they believed international equities would be the best-performing asset over the next five years, compared to just 23% of investors who said they believed US equities would be the top performer.
The US Dollar Index, which measures the dollar against a basket of foreign currencies, has also declined 10% year-to-date.
Laffont said he was now considering purchasing bitcoin.
"Do I own it now? Do I own it tomorrow or in a few days? But every day, I do think, 'Why do I not own it?'" Laffont said. "Sometimes you have to change your mind and you have to say, well, I made a mistake," he added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target

Yahoo

timean hour ago

  • Yahoo

H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target

H.C. Wainwright isn't backing off Summit Therapeutics (NASDAQ: SMMT). On June 2, the firm reaffirmed its Buy rating and maintained a $44 price target, more than double the current $18.21 share price. Analyst targets for the stock now range between $30 and $44.15, with a strong Buy consensus across the board. At a market cap of $13.5 billion, Summit has the attention of the street. The reason is Ivonescimab. It's Summit's checkpoint inhibitor drug, and Wainwright believes it could end up setting a new standard in treating solid tumors. They focused on recent HARMONi trial results. It's not statistically significant on overall survival, but strong enough on other metrics to keep hopes high. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. In particular, they pointed to ivonescimab's progression-free survival hazard ratio of 0.52 when paired with chemo. That compares favorably to the 0.8 seen with Merck's KEYTRUDA in the KEYNOTE-789 trial for the same cancer type—TKI-resistant, EGFR-mutated non-small cell lung cancer. Despite a 30% drop in the stock in the week prior to the price target update, triggered by disappointment over survival stats, Wainwright argued the market is missing the point. No competing drug has hit statistical significance either. They also noted Summit's beta sits at -0.95, which means it tends to move opposite the market, which is something investors might want to consider. While we acknowledge the potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target

Yahoo

timean hour ago

  • Yahoo

H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target

H.C. Wainwright isn't backing off Summit Therapeutics (NASDAQ: SMMT). On June 2, the firm reaffirmed its Buy rating and maintained a $44 price target, more than double the current $18.21 share price. Analyst targets for the stock now range between $30 and $44.15, with a strong Buy consensus across the board. At a market cap of $13.5 billion, Summit has the attention of the street. The reason is Ivonescimab. It's Summit's checkpoint inhibitor drug, and Wainwright believes it could end up setting a new standard in treating solid tumors. They focused on recent HARMONi trial results. It's not statistically significant on overall survival, but strong enough on other metrics to keep hopes high. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. In particular, they pointed to ivonescimab's progression-free survival hazard ratio of 0.52 when paired with chemo. That compares favorably to the 0.8 seen with Merck's KEYTRUDA in the KEYNOTE-789 trial for the same cancer type—TKI-resistant, EGFR-mutated non-small cell lung cancer. Despite a 30% drop in the stock in the week prior to the price target update, triggered by disappointment over survival stats, Wainwright argued the market is missing the point. No competing drug has hit statistical significance either. They also noted Summit's beta sits at -0.95, which means it tends to move opposite the market, which is something investors might want to consider. While we acknowledge the potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Why Symbotic Stock Soared Today
Why Symbotic Stock Soared Today

Yahoo

timean hour ago

  • Yahoo

Why Symbotic Stock Soared Today

Symbotic stock rose today after Arete initiated coverage on the stock with a buy rating. Arete set a one-year price target of $50 per share on the stock, implying additional upside of 43%. Symbotic stock has posted strong gains in 2025, but its valuation profile suggests that shares may still have room to run. 10 stocks we like better than Symbotic › Symbotic (NASDAQ: SYM) stock closed out Wednesday's trading with big gains. The robotics and automation company's share price ended the daily session up 8.5%. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) was flat on the day, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) rose 0.3%. Symbotic stock's rally today was triggered by bullish coverage from an analyst. In a note published this morning, Arete Research initiated coverage on the company and gave its stock a buy rating. With the note it published today, Arete took a bullish stance on Symbotic and set a one-year price target of $50 per share for the stock. The coverage kicked off a wave of buying action, and the stock had been up as much as 10.7% earlier in the daily session. Even after today's gains, Arete's price target implies additional upside of roughly 43% and reflects confidence in continued growth opportunities for the company. Symbotic stock has been on an impressive hot streak in 2025, with excitement surrounding its artificial intelligence (AI) and robotics helping to push the company's share price up 47% year to date. The company now has a market capitalization of roughly $3.8 billion, but it's trading at a reasonable-looking 1.5 times this year's expected sales, and could still have room for substantial valuation upside. While the business posted a net loss of $21 million in its last reported quarter, the robotics specialist managed to grow revenue 40% year over year in the period. Revenue growth could be uneven going forward, but there seems to be a good chance that the company will be able to increase its margins as its business continues to scale. Before you buy stock in Symbotic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Symbotic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Symbotic. The Motley Fool has a disclosure policy. Why Symbotic Stock Soared Today was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store